Price
$127.84+8.41%Social Signal Score
Analyst Ratings
20 analystsRevenue
$224.17M+1235.95%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Quentin S. Blackford
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 2,400
- Beta
- 1.32
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 2.72
Financials
Revenue
$224.17M+1235.9%Net Income
$-381.0KEBITDA
$2.91MFree Cash Flow
$37.52MEPS (diluted)
$-0.01Shares Outstanding (diluted)
32.90M+63.0%Operating Expenses
$151.50MCash & Debt
$591.27MReturn of Capital
$0.00Revenue by Segment (annual)
$747.14MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $747.14M | $-44.55M | $-1.39 |
| 2024 | $591.84M | $-113.29M | $-3.63 |
| 2023 | $492.68M | $-123.41M | $-4.04 |
| 2022 | $410.92M | $-116.16M | $-3.88 |
| 2021 | $322.82M | $-101.36M | $-3.46 |
| 2020 | $265.17M | $-43.83M | $-1.58 |
| 2019 | $214.55M | $-54.57M | $-2.16 |
| 2018 | $147.28M | $-50.38M | $-2.02 |
| 2017 | $99.13M | $-29.74M | $-1.30 |
| 2016 | $64.07M | $-20.90M | $-3.95 |
| 2015 | $36.14M | $-22.80M | $-1.54 |
| 2014 | $21.75M | $-15.83M | $-1.07 |
| 2013 | $15.37M | $-13.59M | $-10.69 |
Valuation
IRTChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·1d ago·Neutral
iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC) today announced that it completed the previously announced acquisition of Vital Connect, Inc. ("VitalConnect"), a leader in wearable biosensor technology and ambulatory cardiac monitoring.
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
iRhythm Provides Update on Cybersecurity Incident Previously Disclosed in June 2026 Following completion of the forensic investigation, company begins notifying impacted individuals Following completion of the forensic investigation, company begins notifying impacted individuals
View source ↗ - Newszacks.com·31d ago·Positive
Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated? iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.
View source ↗ - Newsglobenewswire.com·40d ago·Negative
iRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference SAN FRANCISCO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference.
View source ↗ - Newsseekingalpha.com·46d ago·Negative
iRhythm: The Algorithmic Margin Inflection Changes The Story iRhythm Technologies is evolving from a cardiac patch producer to a comprehensive cardiac monitoring platform, leveraging software and workflow integration for a competitive advantage. Q2 2026 marked a financial inflection: 20.1% revenue growth, 72.8% gross margin, and adjusted EBITDA margin expansion to 19.3%, with raised full-year guidance and record free cash flow. The ZEUS platform's FDA clearance enables significant margin leverag
View source ↗ - Newszacks.com·52d ago·Neutral
iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.
View source ↗ - Newszacks.com·52d ago·Positive
Here's Why iRhythm Holdings, Inc. (IRTC) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·56d ago·Positive
iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $0.02 per share
Typical surprise +55.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.01 vs $-0.04beat
- Thu, Apr 30$-0.43 vs $-0.56beat
- Thu, Feb 19$0.17 vs $0.02beat
- Thu, Oct 30$-0.16 vs $-0.36beat
- Thu, Jul 31$-0.44 vs $-0.53beat
- Thu, May 1$-0.95 vs $-0.89miss
Estimates and results for IRTC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IRTC officers and directors.
- Bought
- $57k
- Sold
- $24.2m
1 trade
56 trades
- Wilson Daniel G.sold
- Blackford Quentin S.sold
- Murphy Patrick Michaelsold
- Patterson Chadsold
- Shrishrimal Sumisold
- Turakhia Minangsold
- Smith Mervinsold
- Rodda Juliannesold
43 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Richard Blumenthalsenate · CT · disclosed Sep 12, 2025 (29d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 12, 2025 (29d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 12, 2025 (29d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 12, 2025 (29d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 12, 2025 (29d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (308d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.